Table 3.
Association between KRAS status and efficacy in PACCE and CAIRO2.
| Response rate, % | Progression-free survival, mo | Overall survival, mo | ||||
|---|---|---|---|---|---|---|
| Wild-type | Mutant | Wild-type | Mutant | Wild-type | Mutant | |
| KRAS | KRAS | KRAS | KRAS | KRAS | KRAS | |
| PACCE oxaliplatin cohort [43] (N = 664) | ||||||
| Ox + Bev + Pmab | 50 | 47 | 9.8 | 10.4 | 20.7 | 19.3 |
| Ox + Bev | 56 | 44 | 11.5 | 11.0 | 24.5 | 19.3 |
| CAIRO2 [47] (N = 528) | ||||||
| Cap, Ox + Bev + Cmab | 61.4 | 45.9 | 10.5 | 8.1 | 21.8 | 17.2 |
| Cap, Ox + Bev | 50.0 | 59.2 | 10.6 | 12.5 | 22.4 | 24.9 |
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation; Pmab: panitumumab.